Elbit Imaging Ltd. (TLV:EMITF)

CTI BioPharma Balance Sheet

Financials in millions ILS. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	39.9	-	27.83	17.42	1.86
Short-Term Investments	-	-	4.25	3.89	0.1
Trading Asset Securities	3.7	-	-	-	-
Cash & Short-Term Investments	43.6	-	32.08	21.31	1.96
Cash Growth	-	-	50.51%	988.96%	-90.27%
Other Receivables	0.39	-	4.01	0.28	0.94
Receivables	25.39	-	4.01	0.68	2.36
Prepaid Expenses	0.02	-	-	0.03	0.05
Other Current Assets	0.3	-	-	-	-
Total Current Assets	69.31	-	36.09	22.02	4.36
Long-Term Investments	0.65	-	5.89	28.31	66.17
Other Long-Term Assets	2.1	1.34	0.08	0.06	0.05
Total Assets	72.06	1.34	64.01	72.27	102.01
Accrued Expenses	1.21	0.38	0.18	0.49	0.86
Other Current Liabilities	0	-	0.55	0.38	6.27
Total Current Liabilities	1.21	0.38	0.73	0.87	7.14
Long-Term Debt	1.87	1.65	-	-	-
Other Long-Term Liabilities	0.62	-	0.62	0.48	0.43
Total Liabilities	3.7	2.04	1.35	1.35	7.56
Common Stock	71.87	-	1,106	1,106	1,106
Additional Paid-In Capital	10.52	8.01	-	-	-
Retained Earnings	-14.03	-8.7	-856.62	-846.24	-823.24
Comprehensive Income & Other	-	-	-186.71	-188.83	-188.61
Total Common Equity	68.36	-0.69	62.66	70.92	94.45
Minority Interest	-0.01	-0	-	-	-
Shareholders' Equity	68.36	-0.7	62.66	70.92	94.45
Total Liabilities & Equity	72.06	1.34	64.01	72.27	102.01
Total Debt	1.87	1.65	-	-	-
Net Cash (Debt)	41.73	-1.65	32.08	21.31	1.96
Net Cash Growth	-	-	50.51%	988.96%	-
Net Cash Per Share	3.92	-0.17	3.54	2.33	0.21
Filing Date Shares Outstanding	11.14	10.64	9.19	9.19	9.19
Total Common Shares Outstanding	11.14	10.64	9.19	9.19	9.19
Working Capital	68.1	-0.38	35.35	21.15	-2.77
Book Value Per Share	6.13	-0.07	6.82	7.72	10.28
Tangible Book Value	68.36	-0.69	62.66	70.92	94.45
Tangible Book Value Per Share	6.13	-0.07	6.82	7.72	10.28

Source: S&P Global Market Intelligence. Standard template. Financial Sources.